Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

Srdan Verstovsek,1 Jason Gotlib,2 Vikas Gupta,3 Ehab Atallah,4 John Mascarenhas,5 Alfonso Quintas-Cardama,1 William Sun,6 Nicholas J Sarlis,6 Victor Sandor,6 Richard S Levy,6 Hagop M Kantarjian,1 Ruben A Mesa71University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Stanford Cancer Institu...

Full description

Bibliographic Details
Main Authors:	Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-12-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/management-of-cytopenias-in-patients-with-myelofibrosis-treated-with-r-a15309

Similar Items

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
by: Mughal TI, et al.
Published: (2014-01-01)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
by: Hans Michael Kvasnicka, et al.
Published: (2018-03-01)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
by: Srdan Verstovsek, et al.
Published: (2017-09-01)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
by: Barosi G, et al.
Published: (2015-05-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
by: Anna Hirano, et al.
Published: (2017-01-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review
by: GUO Huimei, et al.
Published: (2018-08-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by: Srdan Verstovsek, et al.
Published: (2017-02-01)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
by: Stephen Couban, et al.
Published: (2018-09-01)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
by: Francesca Palandri, et al.
Published: (2021-01-01)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
by: Novella Pugliese, et al.
Published: (2019-06-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
by: María Teresa Gómez-Casares, et al.

Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
by: Claire N. Harrison, et al.
Published: (2021-05-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review
by: Farhan Khalid, et al.
Published: (2021-09-01)

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
by: Keith L. Davis, et al.
Published: (2015-01-01)

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera
by: Sylvain Lescuyer, et al.
Published: (2019-03-01)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
by: Moshe Talpaz, et al.
Published: (2018-08-01)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01)

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
by: Vincenzo Accurso, et al.
Published: (2019-03-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

Recent developments in myelofibrosis
by: Mesa RA, et al.
Published: (2012-07-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
by: Prithviraj Bose, et al.
Published: (2020-10-01)

Valproate-Induced Cytopenias
by: J Gordon Millichap
Published: (1990-10-01)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
by: Gowin KL, et al.
Published: (2015-04-01)

STRUCTURE OF CYTOPENIA IN HIV PATIENTS
by: D. V. Baryshnikova, et al.
Published: (2019-05-01)

Refractory Autoimmune Cytopenias Treated With Venetoclax
by: Max J. Gordon, et al.
Published: (2019-06-01)

Clinical Utility of Fedratinib in Myelofibrosis
by: Waksal JA, et al.
Published: (2021-08-01)

Dimorphic anemia and cytopenias
by: Prita Pradhan
Published: (2019-01-01)

Refractory cytopenia of the childhood
by: M Chowdhry, et al.
Published: (2012-01-01)

A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
by: Renato Tavares, et al.
Published: (2020-01-01)